IV form of osteoporosis treatment approved

Article

GlaxoSmithKline and Roche have received FDA approval for Boniva (ibandronate sodium) injection, the first intravenous treatment for postmenopausal osteoporosis. The drug provides an alternative for patients who cannot take an oral medication or are unable to remain upright for 30 to 60 minutes, a requirement when taking the tablet form of bisphosphonates. Ibandronate injection should be administered by a healthcare professional once every three months and will be available early this year.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series
© 2025 MJH Life Sciences

All rights reserved.